0R31 Stock Chart & Stats
$72.98
$0.08(0.11%)
At close: 4:00 PM EDT
$72.98
$0.08(0.11%)
Day’s Range― - ―
52-Week Range$54.50 - $77.01
Previous CloseN/A
Volume2.63K
Average Volume (3M)12.49K
Market Cap
$114.09B
Enterprise Value$142.42K
Total Cash (Recent Filing)$2.37B
Total Debt (Recent Filing)$24.58B
Price to Earnings (P/E)14.4
Beta0.35
Next Earnings
Oct 29, 2026EPS Estimate
1.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.74
Shares Outstanding1,669,743,900
10 Day Avg. Volume3,110
30 Day Avg. Volume12,494
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-27.61
Price to Sales (P/S)4.80
P/FCF Ratio10.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$72.38Price Target Upside-0.83% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)5.68
Revenue Forecast (FY)$20.55B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high net and EBIT margins reflect strong pricing power, premium Marlboro mix and tight cost control. These durable margins support cash generation, shareholder returns and buffer profit volatility as volumes decline, preserving long‑term earnings resilience.
Consistent Cash Generation And FCF ConversionVery high FCF conversion indicates quality of earnings and funds reliable dividends, buybacks and debt servicing. Strong, repeatable cash flow provides durable flexibility to manage maturities and invest in strategic initiatives despite secular industry headwinds.
Product Expansion & Capital Returns DisciplineRapid on! PLUS retail rollout and improving on! share show scalable product traction in oral nicotine, while large, disciplined shareholder returns and ABI equity earnings reinforce capital‑allocation credibility and the ability to monetize diversified cash sources.
Bears Say
High Leverage And Negative EquityVery high debt and negative equity materially reduce financial flexibility, increase interest and refinancing risk, and constrain strategic optionality. A leveraged capital structure amplifies downside to cash‑flow shocks and limits capacity for growth investment.
Persistent Cigarette Volume Declines And Trade‑DownOngoing secular volume erosion and consumer trade‑down reduce premium mix and put pressure on top‑line; reliance on pricing to offset declines is limited over time, risking margin compression and slower revenue growth if discount trends persist.
Oral Tobacco Profitability And Market UncertaintyWeakness in Oral segment from lower shipments and promotional investment undermines a key growth pillar. Combined with illicit e‑vapor market uncertainty, this raises execution risk for diversifying away from cigarettes and delays sustainable revenue replacement.
Altria Group News
0R31 FAQ
What was Altria’s price range in the past 12 months?
Altria lowest share price was $54.50 and its highest was $77.01 in the past 12 months.
What is Altria’s market cap?
Altria’s market cap is $114.09B.
When is Altria’s upcoming earnings report date?
Altria’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were Altria’s earnings last quarter?
Altria released its earnings results on Jul 30, 2026. The company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.496 by -$0.016.
Is Altria overvalued?
According to Wall Street analysts Altria’s price is currently Overvalued.
Does Altria pay dividends?
Altria does not currently pay dividends.
What is Altria’s EPS estimate?
Altria’s EPS estimate is 1.51.
How many shares outstanding does Altria have?
Altria has 1,669,743,900 shares outstanding.
What happened to Altria’s price movement after its last earnings report?
Altria reported an EPS of $1.48 in its last earnings report, missing expectations of $1.496. Following the earnings report the stock price went down -9.209%.
Which hedge fund is a major shareholder of Altria?
Currently, no hedge funds are holding shares in GB:0R31
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altria Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.38 (-0.83% Downside)
$72.38 (-0.83% Downside)
Blogger Sentiment
Bullish
GB:0R31 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.75%
12-Months-Change
Fundamentals
Return on Equity
6.18%
Trailing 12-Months
Asset Growth
3.22%
Trailing 12-Months
Company Description
Altria
Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild. The enterprise further provides an assortment of moist smokeless tobacco products, including Copenhagen, Skoal, Red Seal, and Husky, in addition to its on! brand of oral nicotine pouches. Altria distributes its merchandise chiefly to wholesale partners, such as independent distributors, and directly to substantial retail organizations, including major chain stores. The corporation, founded in 1822, maintains its principal offices in Richmond, Virginia.
0R31 Company Deck
0R31 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized solid financial performance and disciplined execution: EPS growth (Q2 +2.8%, H1 +4.9%), expanded smokeable margins, a narrowed full-year EPS range, substantial shareholder returns (~$3.9 billion YTD), ABI earnings growth (+21.5%), and strategic expansion of the smoke-free on! PLUS offering to ~120,000 stores. Offsetting items included a weaker Oral Tobacco quarter (adjusted OCI down 8% Q2), reported shipment declines affected by trade inventory timing, ongoing cigarette volume declines (adjusted ~-4.5% Q2) and continued consumer trade-down toward discount brands. Management highlighted favorable regulatory and enforcement developments that could benefit regulated smoke-free products over time. On balance, the positives around profitability, cash returns, regulatory tailwinds and product expansion were presented as outweighing near-term volume and segment-specific headwinds.View all GB:0R31 earnings summaries0R31 Revenue Breakdown
88.00% Smokeable products
12.04% Oral tobacco products
-0.06% E-vapor products
0.02% All other
0R31 Stock 12 Month Forecast
Average Price Target
$72.38
▼(-0.83% Downside)
Technical Analysis
British American Tobacco
―
Philip Morris
―
Universal
―
Turning Point Brands
―
RLX Technology
―